Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1985-01-25
1986-01-07
Bond, Robert T.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
2602393P, A61K 3155, C07D40314
Patent
active
045634513
ABSTRACT:
Novel quinazolino-1,4-benzodiazepin-5,13-diones, which have been found to be antagonists of the function of cholecystokinins (CCK), to the preparation of these compounds from compounds prepared by aerobic fermentation of certain Aspergillus alliaceus strains, and to the use of these compounds to antagonize the function of CCK, which antagonism is useful, e.g., for the treatment and prevention of disorders of the gastrointestinal, central nervous and appetite-regulatory systems of mammals, especially of humans.
REFERENCES:
patent: 3651046 (1972-03-01), Derieg et al.
patent: 4187306 (1980-02-01), Mayer et al.
Bock Mark G.
Evans Ben E.
Freidinger Roger M.
Hartman George D.
Bond Robert T.
Elder Richard A.
Merck & Co. , Inc.
Pfeiffer Hesna J.
Szura Daniel T.
LandOfFree
Quinazolino-1,4-benzodiazepin-5,13-diones does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Quinazolino-1,4-benzodiazepin-5,13-diones, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Quinazolino-1,4-benzodiazepin-5,13-diones will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-111871